Company Overview and News
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ECN SIA SIA.DB SLF CMDXF TXCX ECA SLF ECA CMG SLF.PR.G AEM SLFYF POU SLF.PR.B SLF.PR.E PRMRF SLF.PR.D SLF
Sun Life Financial Inc.’s (SLF - Free Report) stock is favored by investors, corroborated by its share price movement. The stock has surged nearly 33% in a year, outperforming its industry's increase of 3.5%. With a market capitalization of $25.7 billion, average volume of shares traded in the last three months were 0.6 million.
DUKH SLF KMPA DUK NMIH SLF KMPR SLF.PR.G GWGH SLFYF SLF.PR.B SLF.PR.E SLF.PR.D SLF
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (The "Company") declares its regular monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B C.WSA MFC.PR.F MFC.PR.C GS.PRB GS.PRA CIFAF GLSSP GWO JBK TFG GS.PRJ GS.PRI MFC 0945 GS.PRD CGBBW GS.PRC CIX SLFYF GS.PRN GWLIF SLF GS.PRK WFCNP FFN NAF.UN SLF WFC.PRL WFC.PRJ TD WFC.PRT GS C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP SLF.PR.G C.PRU WFC.PRY WFC.PRX TD SLF.PR.B WFC.PRW SLF.PR.E WFC.PRV C.PRS SLF.PR.D WFC WFC.WS TNTTF C.PRL C GSC GS.PRICL C.PRJ C.PRK C.PRG GSJ C.PRC SLF GWLOF C.PRPCL MFC.PR.I MFC.PR.J GWO.PR.I MFC GWO.PR.H MFC.PR.H GJS MFC.PR.M GWO.PR.F MFC.PR.N MFC.PR.K MFC.PR.L
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. declares its 170th consecutive monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04375 for each Preferred share ($0.525 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TAC CIFAF TD BCE SLF.PR.G SLF.PR.B TD SLF.PR.E SLF.PR.D TRP TNTTF SLF MFC 0945 MFC.PR.I CIX TRI MFC.PR.J MFC MFC.PR.H SLFYF MFC.PR.M MFC.PR.N MFC.PR.K TU MFC.PR.L SLF
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. II ("Dividend 15 II") declares its regular monthly distribution of $0.04375 for each Preferred share. Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TAC CIFAF BCE SLF.PR.G SLF.PR.B SLF.PR.E SLF.PR.D TRP DF SLF MFC 0945 MFC.PR.I CIX TRI MFC.PR.J MFC MFC.PR.H SLFYF MFC.PR.M MFC.PR.N MFC.PR.K TU MFC.PR.L SLF
Chicago, IL – May 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Home Depot (HD - Free Report) , Merck (MRK - Free Report) , Raytheon (RTN - Free Report) , Eaton (ETN - Free Report) and Sun Life Financial (SLF - Free Report) .
HD LRCX CCS SLF CTXS ETN CDNS MGA HCSG SLF.PR.G SLF.PR.B SLF.PR.E SLF.PR.D CVGI MRK EVRI ASYS ECHO SLF MG FDC MLNX DG SFUN SLFYF SAIC SLF
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Merck (MRK) and Raytheon (RTN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
BBT HD GD SLF ETN SLF XEL SLF.PR.G CSX SLFYF SLF.PR.B SLF.PR.E SLF.PR.D SLF
Most of Manulife's growth has come from their Asia/Pacific segment. This segment will continue to be one of their major focuses going forward.
MFC.PR.B SLF MFC.PR.F MFC.PR.C SLF MFC 0945 VALU MFC.PR.I SLF.PR.G MFC.PR.J MFC MFC.PR.H SLFYF MFC.PR.M SLF.PR.B MFC.PR.N SLF.PR.E MFC.PR.K SLF.PR.D MFC.PR.L SLF
TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- Big 8 Split Inc. (TSX:BIG.D) (TSX:BIG.pr.D) (the “Company”) announced today that it has declared a quarterly dividend of $0.1125 per Class D Preferred Share. In addition, a quarterly dividend on its Class D Capital Shares was declared of $0.043 per Class D Capital Share. The dividends on both the Class D Preferred Shares and Class D Capital Shares are payable on June 15, 2018 to holders of record on May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TD GWO SLF.PR.G SLF.PR.B TD SLF.PR.E SLF.PR.D TNTTF SLF MFC 0945 GWLOF MFC.PR.I MFC.PR.J GWO.PR.I MFC GWO.PR.H MFC.PR.H SLFYF MFC.PR.M GWLIF GWO.PR.F MFC.PR.N MFC.PR.K MFC.PR.L SLF
May 11 (Reuters) - Canada’s main stock index rose on Friday as higher gold prices boosted materials stocks and after tepid jobs data raised the odds that Bank of Canada will hold interest rates steady.
SSRM TNTTF SLF TXCX TD SLF SLF.PR.G SLFYF SLF.PR.B TD SLF.PR.E SLF.PR.D SLF
Sun Life Financial Inc. (SLF - Free Report) reported first-quarter 2018 underlying net income of $609 million (C$770 million), up 14.5% year over year. This improvement was fueled by interest on par seed capital, strong business growth, the lower U.S. income tax rate and favorable investment experience.
TMK SLF LNC.WS TMK SLF LNC TMK.PRC TMK.PRB GM.WS.A GM.WS.B RGA GM.WS.C SLF.PR.G SLFYF GM GM.WSB SLF.PR.B SLF.PR.E SLF.PR.D SLF
May 9 (Reuters) - Canada’s main stock index climbed higher on Wednesday, as oil prices hit 3-1/2-year highs after President Donald Trump pulled the United States out of an international nuclear deal with Iran.
BMQZF ENBBF SLF K TXCX BMO ENB BMO SLF ENB KGC SLF.PR.G EBBNF SLFYF BTE MAXR SLF.PR.B SLF.PR.E SLF.PR.D SLF
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to TSX:SLF / Sun Life Financial Inc. on message board site Silicon Investor.
|IISLF||YDSLF USV Tele|
|Medis E (MDSLF)||USV Tele. YDSLF|
|MER Telemanagement (MTSLF) - Internet/web Co.||MTSLF - Mer Telemanagement|